COVID-19 associated sick days spike in insulin requirements: the need for rapidly escalating treatment and rapidly reducing on recovery

Helen A Casey, Chris Kelly

Keywords


COVID-19, Diabetes Mellitus, severe acute respiratory syndrome coronavirus 2, hyperglycaemia, diabetic ketoacidosis

Full Text:

PDF HTML

References


References

Bornstein ST, Rubinn F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, Boehm B, Amiel S, Holt RIG, Skyler JS, DeVries JH, Renard E,Eckel RH, Zimmet P, Alberti KG, Vidal J, Geloneze B, Chan JCm Ji and Ludwig B. Practical recommendations for the management of diabetes in patients with COVID-19 Lancet Diabetes Endocrinol. 2020 Apr 23 doi: 10.1016/S2213-8587(20)30152-2 Epub ahead of print]

Diabetes UK, Concise advise on inpatient diabetes (COVID:Diabetes): Guidance for managing inpatient hyperglycaemia. Dated 29/4/2020 (Cited 2020 May 26th) Available from: https://www.diabetes.org.uk/resources-s3/public/2020-04/COvID_Hyper_v4.2.pdf

Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol. 2009;302:193–202.

Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47:193–199.




DOI: https://doi.org/10.15277/bjd.2020.261

Refbacks

  • There are currently no refbacks.


The Journal of the Association of British Clinical Diabetologists